Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ImmuCell Corporation before investing.

In this article, we go over a few key elements for understanding ImmuCell Corporation’s stock price such as:

• ImmuCell Corporation’s current stock price and volume
• Why ImmuCell Corporation’s stock price changed recently
• Upgrades and downgrades for ICCC from analysts
• ICCC’s stock price momentum as measured by its relative strength

About ImmuCell Corporation (ICCC)

Before we jump into ImmuCell Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Want to learn more about ImmuCell Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ImmuCell Corporation.

ImmuCell Corporation’s Stock Price as of Market Close

As of May 21, 2026, 12:20 PM, CST, ImmuCell Corporation’s stock price was $9.865.

ImmuCell Corporation is down 0.15% from its previous closing price of $9.880.

During the last market session, ImmuCell Corporation’s stock traded between $9.780 and $10.030. Currently, there are approximately 9.05 million shares outstanding for ImmuCell Corporation.

ImmuCell Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ImmuCell Corporation Stock Price History

ImmuCell Corporation’s (ICCC) price is currently up 16.61% so far this month.

During the month of May, ImmuCell Corporation’s stock price has reached a high of $10.250 and a low of $7.970.

Over the last year, ImmuCell Corporation has hit prices as high as $10.250 and as low as $4.520. Year to date, ImmuCell Corporation’s stock is up 60.41%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ImmuCell Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there were analysts who downgraded ImmuCell Corporation’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate ImmuCell Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ImmuCell Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

ImmuCell Corporation’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ImmuCell Corporation (ICCC) by visiting AAII Stock Evaluator.

Relative Price Strength of ImmuCell Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, ImmuCell Corporation has a weighted four-quarter relative price strength of 19.06%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how ImmuCell Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ImmuCell Corporation Stock Price: Bottom Line

As of May 21, 2026, ImmuCell Corporation’s stock price is $9.865, which is down 0.15% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ImmuCell Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.